Navigation Links
ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
Date:6/30/2008

t Phase IIa clinical trial of patients suffering from post-herpetic neuralgia. In this study, ELADUR showed improved pain control versus placebo during the 3-day continuous treatment period. In addition, ELADUR appeared to be well tolerated overall, and patients treated with ELADUR and placebo exhibited similar safety profiles. A poster describing this study was presented at the 27th Annual Scientific Meeting of the American Pain Society on May 8, 2008 and is accessible on our website (http://www.durect.com/wt/durect/page_name/Publications).

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including Remoxy(TM), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit http://www.durect.com.

NOTE: ORADUR(TM), POSIDUR(TM), ELADUR(TM) and TRANSDUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. Remoxy, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement

The statements in this press release regarding ELADUR, its anticipated attributes and commercial potential, its potential to be a best in class transdermal product for those suffering from PHN and its potential to receive seven years of market exclusivity as an orphan drug are forward-looking statements
'/>"/>

SOURCE DURECT Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
3. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
4. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
5. GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer
6. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
7. Lilly and TransPharma Medical Announce Licensing and Development Agreement
8. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
9. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
10. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
11. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... 15 Ghent University Hospital in Belgium, ... pioneer radiotherapy treatments using arc therapy, has carried ... RapidArc radiotherapy technology from Varian Medical Systems ( ... treated in just 75 seconds, over four times ... "This treatment would have taken more than five ...
(Date:12/15/2009)... -- Today, Hill-Rom Holdings, Inc. (NYSE: ... significant strategic and financial initiatives at its Investor ... is hosted by Peter H. Soderberg, president and ... the following topics: ,, Status of multi-year ... and financial updates Smart technologies that interface ...
(Date:12/15/2009)... 15 Masimo (Nasdaq: MASI ), ... and Low Perfusion pulse oximetry, today announced that ... awarded the 2009 Frost & Sullivan CEO of ... Monitoring market. According to Frost & Sullivan, the ... "unprecedented ability in understanding customer requirements, developing new ...
Breaking Medicine Technology:European Radiotherapy Pioneers Deliver First Varian RapidArc(TM) Treatment for Rectal Carcinoma Patient 2European Radiotherapy Pioneers Deliver First Varian RapidArc(TM) Treatment for Rectal Carcinoma Patient 3Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 2Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 3Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 4Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 5Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 6Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 7Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 2Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 3Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 4Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 5Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6887 1Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6887 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6887 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6887 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6887 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6887 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6887 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6887 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6887 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6887 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6887 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6887 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6887 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6887 14Hissey Kientz LLP Warns Birth Control Pill Users Of Increased Health Risks To Those Who Have Or Are Taking YAZ or YASMIN 63011 1Hissey Kientz LLP Warns Birth Control Pill Users Of Increased Health Risks To Those Who Have Or Are Taking YAZ or YASMIN 63011 2Hissey Kientz LLP Warns Birth Control Pill Users Of Increased Health Risks To Those Who Have Or Are Taking YAZ or YASMIN 63011 3Hissey Kientz LLP Warns Birth Control Pill Users Of Increased Health Risks To Those Who Have Or Are Taking YAZ or YASMIN 63011 4Injury Funds Now To the Rescue with New Lawsuit Funding Service 63006 1Injury Funds Now To the Rescue with New Lawsuit Funding Service 63006 2
... May 11, 2007 /PRNewswire-FirstCall/ --,NicOx S.A. (Eurolist: COX) ... for NCX 1000, which is covered by its ... analysis of 11 patients,from this proof-of-concept study in ... but did not demonstrate the efficacy,required to support ...
... Italy--(BUSINESS WIRE)--May 14, 2007 - Acceleron Pharma,Inc., ... of musculoskeletal, metabolic and cancer-related,diseases, today announced ... demonstrated the ability of the compound to ... and in murine models of,muscular dystrophy. ACE-031 ...
Other Medicine Technology:NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 2NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 3Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 2Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 3
(Date:12/15/2009)... advocates to be leaders in the fight against ... from experts in online learning, the Masie Center ... ONE and Malaria No ... the first-ever "Malaria Griots" program, a dynamic education ... become leaders in the fight against malaria. ...
(Date:12/15/2009)... Dec. 15 Team In Training (TNT), ... charity sports training program, has reached a ... blood cancer research and patient services. ,, For ... pre-eminent charity endurance sports training program, preparing amateurs ... marathon, triathlon, 100-mile century cycle ride or hike ...
(Date:12/15/2009)... CITY, Dec. 15 The new compact LifeSpan ... ( www.LifeSpanFitness.com ), was highly praised by ... treadmills for 2010. The compact TR200 folding treadmill received ... Best Treadmill under $1000. ,, The compact LifeSpan ... in small workout spaces. "This category buster is a ...
(Date:12/15/2009)... reduce depression and fatigue in people struggling with chronic ... from an individual,s sense of mastery over or ... certain physical goals. , The study appears in the ... arguments on fatigue being a symptom of depression," said ... at the University of Illinois and lead author of ...
(Date:12/15/2009)... "For the past decade, the United Nations Foundation has ... proof in the World Malaria Report 2009 that the global strategies ... President for Global Health for the United Nations Foundation , ... ... past decade, the United Nations Foundation has led the ...
Breaking Medicine News(10 mins):Health News:ONE and Malaria No More Launch 'Malaria Griots' 2Health News:ONE and Malaria No More Launch 'Malaria Griots' 3Health News:ONE and Malaria No More Launch 'Malaria Griots' 4Health News:$1 Billion - For Charity! 2Health News:$1 Billion - For Charity! 3Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2Health News:Mastery of physical goals lessens disease-related depression and fatigue 2Health News:Statement by Dr. Daniel Carucci, Vice President for Global Health for the United Nations Foundation, on Progress Shown in World Malaria Report 2009 2
... vessel growth keeps cancers alive have made a world-first ... life-threatening tumours. , Western Australian Institute for Medical ... have found that a gene called RGS5 can reverse ... tumour. , The discovery is published in the most ...
... April 16, 2008 An article published in the ... lack of knowledge regarding cognitive aging in chronic epilepsy ... about the impact of aging on the course of ... of aging (mild cognitive impairment, dementia), or the disease ...
... reach of their High ... Campaign, NEW YORK, April 16 The Ad Council and ... part of their "Boost",national public service advertising campaign designed to encourage ... NBA,All-Star and Captain of the Phoenix Suns, the program features a ...
... April 16 SEIU President Andy,Stern issued the ... delegate elections of SEIU local union United Healthcare,Workers-West ... the voice for member democracy and,then holds an ... members,from running for office tarnishes democracy by its ...
... Cause of Death and Disability, TRENTON, N.J., ... diseases take on the state,s health care system, ... in the health,care, business, labor and faith communities ... (PFCD), a coalition committed to,making chronic disease the ...
... high,cholesterol in their early 40s are more likely to ... research that will be,presented at the upcoming American Academy ... 2008., "Our findings show it would be best ... in their 40s to reduce the risk of,dementia," said ...
Other Medicine News:Health News:World-first discovery could help treat life-threatening tumors 2Health News:Study examines the effect of epilepsy on the aging 2Health News:Video: Phoenix Suns' Amare Stoudemire Kicks Off Program to Encourage Teens to 'Wake Up' and Go to School 2Health News:Video: Phoenix Suns' Amare Stoudemire Kicks Off Program to Encourage Teens to 'Wake Up' and Go to School 3Health News:Video: Phoenix Suns' Amare Stoudemire Kicks Off Program to Encourage Teens to 'Wake Up' and Go to School 4Health News:Video: Phoenix Suns' Amare Stoudemire Kicks Off Program to Encourage Teens to 'Wake Up' and Go to School 5Health News:New Jersey Leaders Join Forces to Battle Chronic Disease 2Health News:New Jersey Leaders Join Forces to Battle Chronic Disease 3Health News:New Jersey Leaders Join Forces to Battle Chronic Disease 4Health News:High Cholesterol in Your 40s Increases Risk of Alzheimer's Disease 2
... Downward Transfer Kit High resolution ,transfer of ... Rapid ,Unique downward capillary transfer allows ... neutral ,(SSC) transfers in three hours. , ... less buffer and blotting paper. Convenient refill ...
... using the Antigen-Antibody Pens-Using a proprietary and ... specialized fountain pens, called Antigen-Antibody pens-TM, that ... the blotting membranes in any form or ... colored dyes helps to see antigen being ...
... the Antigen-Antibody Pens-Using a proprietary and patented ... fountain pens, called Antigen-Antibody pens-TM, that will ... blotting membranes in any form or shape ... dyes helps to see antigen being written ...
... Store 200 to 350 Liters of ... Storage and Distribution of Purified Water,Millipores compact ... to store 200 to 350 liters of ... systems, and to maintain consistent purity of ...
Medicine Products: